18 of 22 (82%) of the third, 20 of 22 (91%) of the fourth, and 19 of 22 (86%) of the fifth measurement. Overall, the results obtained for 17 of 22 (77%) subjects for SAA and 18 of 22 (82%) subjects for CRP were always in agreement with the first results during the study. To measure the intrasubject agreement, the Cohen's k was used: values Ͼ0.80 indicate strong agreement (5 ). For SAA, the k value was 0.818 between the first and second measurements, whereas between the first and third, the first and fourth, and the first and fifth measurements, the k value was always 0.863. For CRP, the k values were 0.912, 0.818, 0.912, and 0.863 between the first and second, the first and third, the first and fourth, and the first and fifth measurements, respectively. Thus, the variability of repeat SAA measurements was comparable to that for CRP.
Heptaminol Interferes in the AxSYM FPIA Amphetamine/ Methamphetamine II Assay
To the Editor:
We report the observation of falsepositive results obtained with the AxSYM ® FPIA Amphetamine/Methamphetamine II assay (Abbott TM ), which is widely used to detect commonly abused amphetamine compounds in human urine. Two hospitalized patients treated with heptaminol chlorhydrate (1905 and 2413 mg daily oral doses, respectively) were positive for urine amphetamine (571 and 777 g/L, respectively), based on a cutoff concentration of 500 g/L. Heptaminol chlorhydrate, a cardiac stimulant and vasodilator, is widely used for the treatment of orthostatic hypotension. Recommended daily oral therapeutic doses for adults are usually 500-1500 mg. After oral administration, heptaminol is rapidly and completely absorbed. Metabolism includes hydroxylation, and nonconjugated forms are found in urine (1 ) . Because intake of amphetamine-related compounds was obviously unlikely and because heptaminol chlorhydrate is not listed as cross-reactant in the package information sheet (2 ), the following investigations were performed because heptaminol (amino-6-methyl-2-heptanol-2 chlorhydrate) and methamphetamine (phenylisopropylmethylamine) have some structural similarity (methylamine group).
A previously published gas chromatography-mass spectrometry method (3, 4) was used to verify the absence of the following amphetamine-related compounds: amfepramone, amphetamine, benzodioxazoylbutanamine, benzphetamine, clobenzorex, dexfenfluramine, dimethoxybromoamphetamine, dimethoxymethylamphetamine, fencamfamin, fenproporex, mefenorex, methamphetamine, methoxyphenamine, methylbenzodioxazolylbutanamine, methylenedioxyamphetamine, methylenedioxyethamphetamine, methylenedioxymethamphetamine, methylphenidate, 4methylthioamphetamine, norephedrine, norfenfluramine, phentermine, and pseudoephedrine. After alkalinization of the patients' urine samples and addition of three deuterated internal standards, the substances of interest were extracted with diethyl ether, derivatized with heptafluorobutyric anhydride, and then purified by successive washing with deionized water and 40 g/L NH 4 OH. Chromatographic separation was performed on a Shimadzu TM GC-17A gas chromatograph equipped with a split/splitless injector and a Supelco TM PTE 5 capillary column [30 m ϫ 0.32 mm (i.d.); 0.25-m film thickness]. Detection was carried out with a Shimadzu QP 5000 mass spectrometric detector in the electronimpact mode, with acquisition in the selected-ion monitoring mode following three mass-to-charge ratios (one for quantification and two for confirmation). This method provided detection limits between 1 and 50 g/L (i.e., low enough to verify positive results obtained with immunochemical assays) for the 23 compounds.
In a second step, heptaminol was measured in urine following precolumn derivatization with o-phthalaldehyde and reversed-phase HPLC with fluorescence detection (5 ) . The chromatography system consisted of a Waters TM M6000A pump and a Hitachi TM F1000 fluorescence spectrophotometer. Before o-phthalaldehyde derivatization, the patients' urines samples were diluted and the internal standard (leucinol) was added. Separation was performed on a C 18 Zorbax (Agilent Technologies TM ) column [15 ϫ 0.46 cm (i.d.)] using the following mobile phase: 450 mL/L acetonitrile in sodium acetate buffer (0.5 g/L) adjusted to a final pH of 6.1 with glacial acetic acid. The flow rate was 1.2 mL/min. The wavelengths for excitation and emission were 338 and 445 nm, respectively. The patients' urine samples were found to contain 887 and 1340 mg/L heptaminol, respectively.
Lastly, heptaminol was added to drug-free urine specimens to determine the response of the AxSYM FPIA assay for amphetamines. The results are presented Table 1 . Because the cutoff concentration was 500 g/L, urine specimens were positive for heptaminol concentrations Ն750 000 g/L.
In conclusion, heptaminol exhibits cross-reactivity (ϳ0.06%) with the AxSYM FPIA Amphetamine/Methamphetamine II assay, but gives false-positive results only with high urine concentrations of heptaminol.
Urinary Sulfur Compounds in Down Syndrome

To the Editor:
We have proposed that hydrogen sulfide contributes to the phenotypes of trisomy 21 (Down syndrome) (1 ). The cystathionine ␤-synthase (CBS; EC 4.2.1.22) gene is located on chromosome 21 (21q22.3). CBS is one of only three enzymes in mammals able to produce hydrogen sulfide in vitro (2, 3 ) . Hydrogen sulfide is oxidized to thiosulfate (4 ), the precursor of sulfite and sulfate anions (5 ) . CBS is overexpressed in fibroblasts of Down syndrome patients (6 ) at amounts ϳ150% higher than in non-Down syndrome individuals. The expression of this gene is even higher in the myeloblasts of Down syndrome patients with leukemia: 12-fold higher than in non-Down syndrome individuals (7 ).
We compared the urinary excretion of sulfur compounds in Down syndrome patients and controls to investigate the prediction that overexpression of CBS increases the production of hydrogen sulfide in these patients. Urinary thiosulfate was determined with the method of Voroteliak et al. (8 ) . We measured urine concentrations of inorganic sulfate by turbidimetry (9 ), cystine and taurine by automated ion-exchange chromatography with ninhydrin detection (Jeol Amino Acid Analyzer), and creatinine by a manual Jaffe method. We studied 17 Down syndrome patients (12 males and 5 females; mean age, 21.6 Ϯ 2.6 years) along with one relative of each patient (a parent or, in some cases, a sibling) as controls. The Down syndrome patients and their relatives received identical diets on the day before urine collection. Informed consent was obtained from Down syndrome patients and their relatives in accordance with the current revision of the Helsinki Declaration of 1975. The first urine produced in the morning was collected in a vial containing 270 mg of boric acid as a 
